Skip to main content
TipRanks
Go Ultimate75% OFF

Provexis (NZCA) AI Stock Analysis

1 Followers
DE:NZCA

Provexis

(Frankfurt:NZCA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue GrowthThe 45.1% revenue increase shows meaningful commercial expansion and suggests stronger product adoption or customer demand. If growth can be maintained, greater scale could improve operating leverage, support investment in Fruitflow and other products, and strengthen the company’s position in functional foods and medical nutrition.
Negative Factors
Persistent UnprofitabilityStrong revenue growth has not yet translated into financial profitability, with operating and net losses continuing and the 2026 net margin remaining near -40%. This unresolved earnings gap limits self-funded expansion, may require continued financing, and makes the business more exposed if growth does not improve margins.

Provexis (NZCA) vs. iShares MSCI Germany ETF (EWG)

-40%-20%0%20%40%60%DE:NZCA-23.08%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 18.88M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-80.5
Beta (1Y)
-11.09
Revenue Growth
-4.92%
EPS Growth
0.00%
Country
Germany
Employees
2
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Provexis Business Overview & Revenue Model

Company Description

Operating globally, Provexis plc, along with its associated companies, specializes in the creation, licensing, and commercialization of functional foods, medical nutritional products, and dietary supplements. A key offering is Fruitflow, a unique tom...

Provexis Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:NZCA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:EAHGB:EAH61NeutralGBP 58.27M26.632.55%―9.96%29.72%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:STXGB:STX43NeutralGBP 34.37M-4.3164.57%―36.19%60.75%
GB:CHLLGB:CHLL38UnderperformGBP 836.68K-0.00233.76%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:NZCAGB:EAHGB:CHLLGB:HELDGB:STXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:NZCA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:NZCAProvexis plc0.01-0.00-23.08%
GB:EAHEco Animal Health81.50-6.00-6.86%
GB:CHLLChill Brands Group PLC1.60-8.40-84.00%
GB:HELDMountfield Group plc0.90-0.05-5.26%
GB:STXShield Therapeutics3.00-3.65-54.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.